Nature Medicine

07/21/2025

ICYMI Bill Gates wrote a World View about how his father's death from Alzheimer's disease prompted him to support a global collaboration of top dementia researchers to accelerate proteomics discovery.
Read Bill Gates here: https://ow.ly/sFtf50WsN04
News summary: https://ow.ly/YXqm50WsN05
All the content: https://ow.ly/20Ny50WsN06

The Global Neurodegeneration Proteomics Consortium is a multi-national database that aims to leverage proteomics and clinical data to understand and improve ...

07/21/2025

Preliminary results from a phase 1/2 trial show that an AAV-OTOF gene therapy is safe and leads to hearing improvements in 10 patients with congenital deafness with 6-12 months follow up, including a teenager and a young adult, expanding the age range from previous trials.

Preliminary results from an investigator-initiated clinical trial showed that an AAV-OTOF gene therapy was safe and led to hearing improvements in...

07/21/2025

Our latest Review summarizes the current knowledge on mortality-defining toxicities of therapies, beyond CRS and ICANS. & colleagues discuss underlying mechanisms of rare and long-term toxicities and how these affect timing and management, and outline key unmet needs and future priorities.

Chimeric antigen receptor (CAR) T cell therapy is associated with a unique spectrum of toxicities that drive morbidity, mortality and patient...

07/21/2025

In a silent trial involving 197 lung cancer patients over the span of four months, a pathology foundation model was able to identify presence of EGFR mutations with high accuracy, potentially preventing further genetic testing in 43% of cases.

07/18/2025

therapies for have entered the clinic; our latest Review summarizes the advances that got us here, lessons learned from early trials & the clinical, manufacturing & regulatory challenges that must now be overcome

07/18/2025

Read about the scientific and technological breakthroughs reshaping transplant medicine - including the transformative role of AI, xenotransplantation and tissue engineering, and novel approaches to immunosuppression.

Organ transplantation remains the sole definitive treatment for many forms of end-stage organ failure, yet donor organ shortages impose...

07/18/2025

An explosion of and is catalyzing innovations in the mission to scale up support worldwide. These paradigms currently rely on a ‘human in the loop’ — but who is the human in question, and does it matter? News & Views from Anushka Patel and Ernesto Isaac Lara

An explosion of digital tools and AI is catalyzing innovations in the mission to scale up mental health support worldwide. These paradigms...

07/18/2025

In this multicenter phase 1 trial, patients with advanced gastric and gastroesophageal junction cancer were safely treated with the CLDN18.2- targeting antibody drug conjugate SHR-A1904, leading to encouraging objective response rates.

Claudin-18 isoform 2 (CLDN18.2), a tight junction protein expressed in non-malignant gastric epithelium and exposed on tumor cell surface during...

07/18/2025

In this phase 1 trial, treatment with IBI343, a CLDN18.2- targeting antibody drug conjugate, was safe and showed encouraging clinical responses in patients with advanced gastroesophageal junction adenocarcinoma.

Aberrant expression of claudin18.2 (CLDN18.2) has frequently been observed in gastric and gastroesophageal junction (G/GEJ) adenocarcinoma, making...

07/18/2025

In a prospective study including 2,300 pediatric and adult patients with liquid and solid tumors, RNA sequencing provided actionable molecular information in 87% of cases, including for diagnostic and therapy matching purposes.

Molecular diagnostics in oncology uses next-generation sequencing to improve diagnostic precision, prognostic prediction and therapeutic target...

07/17/2025

When tested in a multiethnic cohort of ~2.5 million US veterans, the PREVENT equations, recently developed by the American Heart Association for sex-specific and race-free prediction of cardiovascular disease risk, were shown to accurately estimate this risk with some variability across race and ethnicity groups and to outperform the previously used PCE risk score.

When tested in a multiethnic cohort of ~2.5 million US veterans, the PREVENT equations, recently developed by the American Heart Association for...

07/17/2025

, chair of Gates ventures which helped funded the Global Neurodegeneration Proteomics Consortium, writes in a World View about his personal history with Alzheimer’s Disease, losing his father to the disease in 2020. https://www.nature.com/articles/d41591-022-00044-w